NXS (ASX) The matrix: “Think of it like a slimy bomb shelter” .....

Originally posted by sabine: ↑

“Sydney wound care company making ASX gains

View attachment 1593181
Sydney company Next Science has a suite of products aimed at breaking down germ "biofilm". (AAP)

Shares in Next Science are have more than tripled since their ASX debut last month, as the Sydney company takes on the "slimy bomb shelter" where germs live.
FRIDAY JUNE 7;
UPDATED 5 DAYS AGO
A Sydney biotech company devoted to treating chronic wounds by taking on the "force shield" where germs hang out has more than trebled in value since its ICO six weeks ago.

Backed by billionaire property developer Lang Walker, Next Science was up 30.6 per cent last week and has soared since its mid-April ASX debut to close at $3.63 on Friday.

The company has a suite of gels and washes aimed at tackling "biofilm," a cellular matrix where as much as 90 per cent of bacteria can be found.

"Think of it like a slimy bomb shelter, one that's bound together so tightly that antibiotics can't get it," chief executive Judith Mitchell said.

"If it were a Star Wars film, think of it like a force shield. We go in and down the shield."

Next Science has four products approved for sale in the US, aimed at treating chronic wounds and preventing post-surgical infections.

They should all be available in Australia next year, with sales of an over-the-counter treatment for chronic acne - also a biofilm - slated to begin this year.

Ms Mitchell said gels and washes have been used to treat 90,000 patients, with its BlastX chronic wound care gel in some cases successfully treating year-old wounds.

"Patients are turning to us when really nothing else has worked," she said.

Because the gels don't rely on antibiotics, antibiotic resistance isn't an issue, Ms Mitchell said.

Ten million people around the world have chronic wounds, including 433,000 in Australia, costing the healthcare system $2.6 billion a year, Ms Mitchell said.

3M is distributing BlastX, while Zimmer Biomet and Grace Medical are selling the company's other products.

Next Science was founded in 2012 by Florida researcher Matthew Myntti, and Mr Walker ended up funding the company for its first five years after hearing about it on the board of Neuren Pharmaceuticals.

The wife of a board member and Dr Myntti's wife share a cousin, Ms Mitchell said.

"True luck. This was just a serendipitous situation."

Serendipitous for Dr Myntti - and for Mr Walker, who now owns 42.42 per cent of a $665 million company.

While many small biotech companies are acquired, Ms Mitchell said Next Science's product line was likely too diverse for that and 65 per cent of its shares are in escrow anyway.

"Nobody's going anywhere for two years," she said.

Instead Next Science is looking to add new products to prevent keloid scars and treat bacterial vaginosis, atopic dermatitis, nail fungus and the skin condition impetigo, as well as partnering with other companies for research, development and commercialisation.

"We can be a disinfectant, we can clean surfaces for food, we can grow crops, we can do lots of stuff," Ms Mitchell said.

SOURCE AAP
https://www.sbs.com.au/news/sydney-wound-care-company-making-asx-gains

Thankyou’S are in order and I guess I better get some shares again.

More scientific explanations of what Next Science is about is in these research posters produced for a major symposium on Advanced Wound Care over several days in https://www.sawcspring.com/ in San Antonio, Texas in early May

View attachment 1593148
View attachment 1593157
https://www.nextscience.com/2019/05/27/sawc-spring-2019-posters/

The next one, in October will be Las Vegas ...

Expand

70,000 patients reported to have used washes and gels in interviews at the beginning of May and now 90,000 on 1 June. Big month!

Also, list of future solutions is growing to now cover keloid scars, bacterial vaginosis, atopic dermatitis, nail fungus, impetigo, surface disinfectant, growing crops, cystic fibrosis, sinusitis, amongst others.

No.	Vol.	Price($)
2	34218	25.0¢

No.

Vol.

Price($)

34218

25.0¢

Price($)	Vol.	No.
27.0¢	29523	2

Price($)

Vol.

No.

27.0¢

29523

No.	Vol.	Price($)
2	34218	0.250
1	10490	0.245
2	10420	0.240
1	4255	0.235
4	35752	0.220

No.

Vol.

Price($)

34218

0.250

10490

0.245

10420

0.240

4255

0.235

35752

0.220

Price($)	Vol.	No.
0.270	29523	2
0.290	49506	2
0.295	3390	1
0.300	1298	1
0.310	45789	1

Price($)

Vol.

No.

0.270

29523

0.290

49506

0.295

3390

0.300

1298

0.310

45789

(20min delay)
Last 26.0¢		Change 0.005(1.96%)		Mkt cap ! $75.96M

Open	High	Low	Value	Volume
26.0¢	26.0¢	25.0¢	$81.24K	313.3K

The matrix: “Think of it like a slimy bomb shelter” ....., page-2

Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings

Koba jumps on uranium rock chips grading over 7% as uranium price revival evidence mounts

INOVIQ says it has found a way to test blood for Parkinson's Disease – after Alzheimer's success in June

Monadelphous profits up 16.2% on strong revenue result, and the market likes it

St George Mining jumps 8% on news it's appointed two niobium executives – from the world's biggest player, CBMM

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

The matrix: “Think of it like a slimy bomb shelter” ....., page-2

Top Stories

Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings

Koba jumps on uranium rock chips grading over 7% as uranium price revival evidence mounts

INOVIQ says it has found a way to test blood for Parkinson's Disease – after Alzheimer's success in June

Monadelphous profits up 16.2% on strong revenue result, and the market likes it

St George Mining jumps 8% on news it's appointed two niobium executives – from the world's biggest player, CBMM

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News